Table 2. Characteristics of CD patients with and without SIBO.
| Variables | SIBO+ (n=34) | SIBO− (n=39) | P |
|---|---|---|---|
| Males | 17 (50.0) | 25 (64.1) | 0.224 |
| Age at diagnosis (years) | 20.0 (15.5–38.5) | 23.0 (21.0–33.0) | 0.711 |
| Disease duration (months) | 44.4 (10.3–85.6) | 38.6 (18.7–70.0) | 0.916 |
| Montreal location | 0.455 | ||
| L1 (ileal) | 13 (38.2) | 10 (25.6) | 0.248 |
| L2 (colonic) | 4 (11.8) | 4 (10.3) | 1.000 |
| L3 (ileocolonic) | 17 (50.0) | 24 (61.5) | 0.322 |
| Isolated L4 (upper GI tract) | 0 (0.0) | 1 (2.6) | 1.000 |
| Small bowel lesions | 31 (91.2) | 34 (87.2) | 0.865 |
| Montreal behavior at diagnosis | |||
| B1 (non-stricturing, non-penetrating) | 15 (44.1) | 25 (64.1) | 0.087 |
| B2 (stricturing) | 16 (47.1) | 13 (33.3) | 0.232 |
| B3 (penetrating) | 3 (8.8) | 1 (2.6) | 0.511 |
| P (perianal disease) | 15 (44.1) | 17 (43.6) | 0.964 |
| Previous bowel resection | 8 (23.5) | 4 (10.3) | 0.127 |
| Current medication | |||
| 5-ASA | 23 (67.6) | 31 (79.5) | 0.250 |
| Steroids | 0 (0.0) | 3 (7.7) | 0.289 |
| Immunomodulator | 5 (14.7) | 6 (15.4) | 0.936 |
| Anti-TNF | 3 (8.8) | 2 (5.1) | 0.874 |
| EEN | 23 (67.6) | 31 (79.5) | 0.250 |
| WBC (×109/L) | 6.4 (4.4–7.5) | 4.7 (3.3–5.0) | 0.207 |
| Hemoglobin (g/L) | 130 (112–142) | 128 (112–142) | 0.082 |
| Platelet count (×109/L) | 288 (166–384) | 197 (163–254) | 0.116 |
| Albumin (g/L) | 44.8 (41.9–46.7) | 42.3 (35.3–44.8) | 0.974 |
| C-reactive protein (mg/L) | 2.2 (0.9–5.0) | 1.9 (0.5–7.3) | 0.946 |
| ESR (mm/h) | 13 [6–29] | 7 [5–21] | 0.189 |
| Interleukin-6 (ng/L) | 8.24 (5.44–11.01) | 6.08 (4.78–10.14) | 0.476 |
| Fecal calprotectin (μg/g), n=56 | 489.1 (397.0–682.9) | 205.1 (41.1–852.4) | 0.416 |
Data are n (%) or median (IQR). n, number; IQR, interquartile range; CD, Crohn’s disease; SIBO, small intestinal bacterial overgrowth; 5-ASA, 5-aminosalicylic acid; TNF, tumor necrosis factor; EEN, exclusive enteral nutrition; WBC, white blood cell count; ESR, erythrocyte sedimentation rate.